Item 7.01 Regulation FD Disclosure.
On January 7, 2019, VistaGen Therapeutics, Inc. (the "Company") began utilizing
a new corporate presentation. A copy of the Corporate Presentation is attached
hereto as Exhibit 99.1.
The information in this Item 7.01 of this Current Report on Form 8-K, including
the information set forth in Exhibit 99.1, is being furnished and shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), nor shall Exhibit 99.1 filed herewith be
deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as shall be expressly set forth by
specific reference in such a filing.
In addition, this Current Report on Form 8-K and the exhibit(s) attached hereto
may contain, among other things, certain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, including,
without limitation, (i) statements with respect to the Company's plans,
objectives, expectations and intentions; and (ii) other statements identified by
words such as "may", "could", "would", "should", "believes", "expects",
"anticipates", "estimates", "intends", "plans" or similar expressions. These
statements are based upon the current beliefs and expectations of the Company's
management and are subject to significant risks and uncertainties.
Item 9.01 Exhibits.
See Exhibit Index.
© Edgar Online, source Glimpses